HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
6.50
+0.20 (+3.17%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close6.30
Open6.25
Bid6.25 x 0
Ask6.50 x 0
Day's Range6.12 - 6.50
52 Week Range4.40 - 89.44
Volume11,850
Avg. Volume38,296
Market Cap50.805M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.93
Earnings DateAug 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11

    FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD Pharma" or the "Company") announces that Edward Brennan, MD, President, BioSciences Division, will present an overview of the Company at the 12th Annual LD Micro Main Event Investor conference at 12:20 p.m. PT/3:20 p.m. ET on Wednesday, December 11, 2019 at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.

  • Business Wire

    FSD Pharma Reports Third Quarter 2019 Financial Results

    These financial results are unaudited, are prepared in accordance with International Financial Reporting Standards (IFRS) and are reported in Canadian dollars. The Company intends to initiate Phase 1 first-in-human safety and tolerability trials for its lead candidate, PP 101 micro-PEA during 1Q20.

  • Newsfile

    Canadian Securities Exchange Attracts First Israeli Company Listings

    IM Cannabis becomes third Israeli cannabis listing in past six weeks Toronto, Ontario--(Newsfile Corp. - November 5, 2019) - The Canadian Securities Exchange ("CSE" or "the Exchange") welcomes the listing of three Israel-based companies on the Exchange over the past six weeks: InnoCan Pharma Corp. (CSE: INNO), Isracann Biosciences Inc. (CSE: IPOT), and IM Cannabis Corp. (CSE: IMCC), which began trading today. ...

  • FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering
    CNW Group

    FSD Pharma Second Tranche of Private Placement Closes, Total of $4.59 Million Raised at $20.10 To Date, Extends Offering

    TORONTO , Nov. 4, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (OTCQB:FSDDD) (0K9.F) ("FSD" or the "Company") announces that it has closed a second tranche of its previously announced private placement (the "Private Placement"), and has now raised total gross proceeds of CAD $4,596,285 from investors, including members of senior management and the Board of Directors, issuing an aggregate of 228,671 class B subordinate voting shares (the "Shares"). The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws. The Company expected to close the Private Placement by October 31, 2019 , however, it has elected to extend the Private Placement to accommodate potential additional interest from institutional grade investors.

  • Newsfile

    FSD Pharma, New Sales License is a Key Development, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - Executive Co-Chairman and CEO of FSD Pharma, Dr. Raza Bokhari, speaks about the company's sales license which allows FSD to serve the growing medicinal user market in Canada.If you cannot view the video above, please visit:https://www.b-tv.com/fsd-pharma-sales-license-ceo-clip-90sec/FSD Pharma Inc. (CSE: HUGE)fsdpharma.comAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. These 90 second video profiles ...

  • FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018
    CNW Group

    FSD Pharma Announces the Filing of an Amended Annual MD&A for 2018

    TORONTO , Oct. 23, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") announces that an amended and restated management's discussion and analysis for the year ended December 31, 2018 (the "Amended 2018 MD&A") has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission ("OSC") of the Company's disclosure record. The Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company's disclosure.

  • HUGE.CN: FSD Pharma Undergoes Share Consolidation in Management’s Effort to Uplist in the U.S.
    Zacks Small Cap Research

    HUGE.CN: FSD Pharma Undergoes Share Consolidation in Management’s Effort to Uplist in the U.S.

    By Steven Ralston, CFA CSE:HUGE.CN | OTC:FSDDD READ THE FULL HUGE.CN RESEARCH REPORT FSD Pharma Inc. (CSE:HUGE.CN) (OTC:FSDDD) is a cannabis-platform company which is targeting many verticals that compose the legal cannabis industry. The platform can be bifurcated into two components. One, management is concentrating on the cultivation, processing and distribution of high quality,

  • Newsfile

    InvestmentPitch Media Feature Video Discusses FSD Pharma and a Recent Commentary by CEO Raza Bokhari, MD - Video is Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 22, 2019) - Today's feature company is FSD Pharma Inc. (CSE:HUGE) (FSE:0K9) (OTCQB:FSDDD), which is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.InvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and ...

  • Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's New OTCQB Symbol and Appointment of Former U.S. Congressman Stephen Buyer to its Board of Directors - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 18, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDD) announced that its Class B shares, which trade on the OTCQB, will have a new symbol FSDDD for a period of 20 business days until November 13th, at which time the symbol will revert back to FSDDF. The temporary change is protocol for stocks that trade on US exchanges that undergo structural events, such as ...

  • Business Wire

    FSD Pharma Announces Temporary Change in OTCQB Ticker Symbol to FSDDD

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company”) today announced that the Company’s Class B Shares are trading on the OTCQB under the ticker symbol FSDDD for 20 business days, effective as of October 16, 2019. The temporary change is protocol for exchange stocks that undergo structural events, such as the 1:201 share consolidation announced by FSD Pharma on October 11, 2019 to advance the Company’s strategic plan to increase visibility among U.S. investors and list on a major U.S. exchange. FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis.

  • FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation
    CNW Group

    FSD Pharma Appoints Former Member of U.S. Congress to its Board of Directors, Announces Share Consolidation

    TORONTO , Oct. 11, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") today announced the appointment of former U.S. congressman Stephen Buyer to the Company's Board of Directors. The Company also announced that it will complete a consolidation of its class A multiple voting shares ("Class A Shares") and its class B subordinate voting shares ("Class B Shares" and collectively with the Class A Shares, the "FSD Shares"), each on a 1 to 201 basis (the "Consolidation").

  • FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering
    CNW Group

    FSD Pharma Closes First Tranche of Private Placement at $4.58 Million, Extends Offering

    TORONTO , Oct. 1, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company") is pleased to provide an update on its previously announced private placement of its class B subordinate voting shares ("Shares") at a price of CAD$0.10 per Share (the "Private Placement").  On September 30, 2019 , the Company closed an initial tranche of the Private Placement, raising gross proceeds of CAD $4,583,085 from investors, including members of senior management and board of directors, and issuing an aggregate of 45,830,850 Shares. The Shares issued to purchasers in Canada will be subject to a four-month hold period, in accordance with applicable Canadian securities laws.

  • Newsfile

    InvestmentPitch Media Video Discusses FSD Pharma's LOI with World Class Extractions Creating JV to Build and Operate Cannabis Extraction/Processing Facility in Cobourg, Ontario - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - September 26, 2019) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), through its wholly-owned subsidiary FV Pharma, has signed a letter of intent with World Class Extractions (CSE: PUMP) (FSE: WCF) to create a joint venture to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario. FSD Pharma and World Class Extractions will each hold a 50% interest in the new joint venture, ...

  • FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center
    CNW Group

    FSD Pharma Signs LOI to Establish Joint Venture with World-Class Extractions to Deploy Full Extraction Processing Center

    TORONTO , Sept. 25, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (FSDDF) (FRA: 0K9) ("FSD Pharma", "FSD" or "the Company") today announced the signing of a letter of intent ("LOI") to establish a joint venture (the "Joint Venture") with the Company's wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), and World-Class Extractions Inc. ("World-Class") (CSE:PUMP) (WCF.F) to develop, manage and operate a cannabis extraction and processing facility in Cobourg, Ontario (the "Facility") to extract various cannabidiol and other valuable elements from cannabis and hemp plants.

  • HUGE.CN: Zacks Initiates Coverage of FSD Pharma Inc.
    Zacks Small Cap Research

    HUGE.CN: Zacks Initiates Coverage of FSD Pharma Inc.

    By Steven Ralston, CFA CSE:HUGE.CN | OTC:FSDDF READ THE FULL HUGE.CN RESEARCH REPORT FSD Pharma Inc. (CSE:HUGE.CN) (OTC:FSDDF) is a cannabis-platform company which is targeting many verticals that compose the legal cannabis industry. The platform can be bifurcated into two components. One, management is concentrating on the cultivation, processing and

  • Market Exclusive

    FSD Pharma Launches Online System for Medicinal Cannabis Orders

    FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) has launched its online ordering system for the direct fulfillment of medicinal cannabis orders. Clients having a prescription from a medical practitioner or a registration number with Health Canada can now place an order online for dried cannabis on FVPharma.com. FSD Pharma subsidiary FV Pharma will handle the system. "The launch of a functional online ordering portal […]The post FSD Pharma Launches Online System for Medicinal Cannabis Orders appeared first on Market Exclusive.

  • FSD Pharma Announces Private Placement
    CNW Group

    FSD Pharma Announces Private Placement

    TORONTO , Aug. 30, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (0K9.F) ("FSD" or the "Company") is pleased to announce that the Company has launched a private placement of up to US$5 million of its class B subordinate voting shares ("Shares") at a price of C$0.10 per Share without any warrant coverage (the "Private Placement"). The Company expects to close the Private Placement by September 30 , 2019. To date, C$1,314,000 million of proceeds have been committed and received. The CEO has personally invested US$500,000 and the FSD Pharma leadership team, representing founders, directors and members of the senior management team have collectively invested more than C$500,000 .

  • FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment
    CNW Group

    FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment

    FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment